Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,536 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01327053 | A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma(BOLT) | completed | Phase 2 | 230 | Novartis PharmaceuticalsINDUSTRY | 12 | Aug 28, 2019 | clinicaltrials |
| NCT02279862 | Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive | completed | Phase 2 | 82 | Bristol-Myers SquibbINDUSTRY | 9 |
| Aug 28, 2019 |
| clinicaltrials |
| NCT01574716 | Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation(SOURCE) | completed | Phase 2 | 209 | MorphotekINDUSTRY | 6 | Aug 21, 2019 | clinicaltrials |
| NCT02759783 | Conventional Care Versus Radioablation (Stereotactic Body Radiotherapy) for Extracranial Oligometastases(CORE) | unknown | Phase 2 / Phase 3 | 245 | Royal Marsden NHS Foundation TrustOTHER | 2 | Aug 21, 2019 | clinicaltrials |
| NCT00027846 | Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma | completed | Phase 2 | 378 | Children's Oncology GroupNETWORK | 6 | Aug 7, 2019 | clinicaltrials |
| NCT00238264 | Radiation Therapy in Treating Young Patients With Gliomas | completed | Phase 2 | 92 | Children's Oncology GroupNETWORK | 6 | Aug 7, 2019 | clinicaltrials |
| NCT01236352 | Multiple Ascending Dose of BMS-911543 | terminated | Phase 1 / Phase 2 | 98 | Bristol-Myers SquibbINDUSTRY | 2 | Jul 31, 2019 | clinicaltrials |
| NCT02046070 | Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma | completed | Phase 2 | 148 | Millennium Pharmaceuticals, Inc.INDUSTRY | 5 | Jul 17, 2019 | clinicaltrials |
| NCT02023697 | Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone | completed | Phase 2 | 391 | BayerINDUSTRY | 15 | Jul 12, 2019 | clinicaltrials |
| NCT01531894 | Continuation Study of the Oral AKT Inhibitor GSK2110183 | completed | Phase 2 | 11 | Novartis PharmaceuticalsINDUSTRY | 5 | Jul 9, 2019 | clinicaltrials |
| NCT01006395 | Prevention of Micro-architectural Bone Decay in Males With Non-metastatic Prostate Cancer Receiving Androgen Deprivation Therapy (ADT) | completed | Phase 2 / Phase 3 | 64 | Austin HealthOTHER_GOV | 1 | Jul 5, 2019 | clinicaltrials |
| NCT01072175 | Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212 | completed | Phase 2 | 430 | Novartis PharmaceuticalsINDUSTRY | 2 | Jul 5, 2019 | clinicaltrials |
| NCT01367665 | STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma | completed | Phase 2 | 1,232 | Hoffmann-La RocheINDUSTRY | 37 | Jun 6, 2019 | clinicaltrials |
| NCT01289041 | BKM120 as Second-line Therapy for Advanced Endometrial Cancer | completed | Phase 2 | 70 | Novartis PharmaceuticalsINDUSTRY | 13 | May 30, 2019 | clinicaltrials |
| NCT02039947 | Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain | completed | Phase 2 | 127 | Novartis PharmaceuticalsINDUSTRY | 7 | May 21, 2019 | clinicaltrials |
| NCT02306291 | Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML | completed | Phase 1 / Phase 2 | 91 | GlycoMimetics IncorporatedINDUSTRY | 3 | May 17, 2019 | clinicaltrials |
| NCT02780167 | Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis | completed | Phase 2 | 269 | PfizerINDUSTRY | 5 | May 2, 2019 | clinicaltrials |
| NCT02632786 | The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis(PRONTO) | completed | Phase 2 | 129 | Prothena Biosciences Ltd.INDUSTRY | 10 | Apr 5, 2019 | clinicaltrials |
| NCT00735917 | Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 3 | Apr 2, 2019 | clinicaltrials |
| NCT01685138 | LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer | completed | Phase 2 | 124 | Novartis PharmaceuticalsINDUSTRY | 18 | Mar 26, 2019 | clinicaltrials |
| NCT03154047 | Study in Subjects With Light Chain (AL) Amyloidosis | terminated | Phase 2 | 80 | Prothena Biosciences Ltd.INDUSTRY | 10 | Mar 26, 2019 | clinicaltrials |
| NCT02472145 | An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy | completed | Phase 2 / Phase 3 | 326 | Janssen Research & Development, LLCINDUSTRY | 14 | Mar 19, 2019 | clinicaltrials |
| NCT01907100 | Nintedanib (BIBF 1120) in Mesothelioma | terminated | Phase 2 / Phase 3 | 545 | Boehringer IngelheimINDUSTRY | 27 | Mar 18, 2019 | clinicaltrials |
| NCT01685255 | A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy | terminated | Phase 2 | 83 | Incyte CorporationINDUSTRY | 6 | Mar 11, 2019 | clinicaltrials |
| NCT01997333 | Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer(METRIC) | completed | Phase 2 | 327 | Celldex TherapeuticsINDUSTRY | 9 | Mar 8, 2019 | clinicaltrials |
| NCT01881230 | Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)(tnAcity) | completed | Phase 2 / Phase 3 | 191 | CelgeneINDUSTRY | 12 | Feb 21, 2019 | clinicaltrials |
| NCT00061893 | Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors | completed | Phase 2 | 38 | Children's Oncology GroupNETWORK | 4 | Feb 15, 2019 | clinicaltrials |
| NCT02129556 | Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer(PANACEA) | completed | Phase 1 / Phase 2 | 58 | ETOP IBCSG Partners FoundationNETWORK | 5 | Feb 15, 2019 | clinicaltrials |
| NCT01337401 | A Trial of Cediranib in the Treatment of Patients With Alveolar Soft Part Sarcoma (CASPS)(CASPS) | unknown | Phase 2 | 36 | Institute of Cancer Research, United KingdomOTHER | 3 | Jan 24, 2019 | clinicaltrials |
| NCT01420081 | A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer | terminated | Phase 2 | 67 | PfizerINDUSTRY | 8 | Jan 8, 2019 | clinicaltrials |
| NCT01959282 | A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis | completed | Phase 2 | 219 | Janssen Research & Development, LLCINDUSTRY | 14 | Jan 4, 2019 | clinicaltrials |
| NCT02391116 | Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) | completed | Phase 2 | 67 | BayerINDUSTRY | 10 | Jan 4, 2019 | clinicaltrials |
| NCT01936363 | Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer | completed | Phase 2 | 65 | EMD SeronoINDUSTRY | 7 | Dec 12, 2018 | clinicaltrials |
| NCT01824693 | Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia | completed | Phase 2 | 30 | Children's Oncology GroupNETWORK | 4 | Dec 5, 2018 | clinicaltrials |
| NCT01864798 | A Study to Evaluate Denosumab in Young Patients With Primary Breast Cancer(D-Beyond) | terminated | Phase 2 | 27 | Jules Bordet InstituteOTHER | 2 | Nov 27, 2018 | clinicaltrials |
| NCT02044822 | Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion | terminated | Phase 2 | 102 | Gilead SciencesINDUSTRY | 14 | Nov 19, 2018 | clinicaltrials |
| NCT00782067 | Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia | completed | Phase 2 | 116 | Novartis PharmaceuticalsINDUSTRY | 12 | Nov 15, 2018 | clinicaltrials |
| NCT03736122 | A Study of Syngenon (BSG-001) for Inhalation in Subjects With Malignant Pleural Effusion and/or Malignant Ascites | unknown | Phase 1 / Phase 2 | 58 | BioSyngen Pte LtdINDUSTRY | 1 | Nov 8, 2018 | clinicaltrials |
| NCT01801111 | A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment | completed | Phase 1 / Phase 2 | 138 | Hoffmann-La RocheINDUSTRY | 16 | Nov 2, 2018 | clinicaltrials |
| NCT00641095 | Phase III, Multicentre, Randomised Study of Fludarabine/Cyclophosphamide Combination With or Without Rituximab in Patients With Untreated Mantle Cell Lymphoma(MCLPIII) | completed | Phase 2 / Phase 3 | 370 | University College, LondonOTHER | 2 | Oct 31, 2018 | clinicaltrials |
| NCT00281632 | A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer | completed | Phase 2 | 35 | GlaxoSmithKlineINDUSTRY | 3 | Sep 17, 2018 | clinicaltrials |
| NCT01923168 | Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women | completed | Phase 2 | 340 | Novartis PharmaceuticalsINDUSTRY | 17 | Sep 14, 2018 | clinicaltrials |
| NCT01304524 | A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3(HPV-003) | completed | Phase 2 | 167 | Inovio PharmaceuticalsINDUSTRY | 9 | Sep 7, 2018 | clinicaltrials |
| NCT00741260 | Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer | completed | Phase 1 / Phase 2 | 105 | Puma Biotechnology, Inc.INDUSTRY | 11 | Sep 5, 2018 | clinicaltrials |
| NCT00467051 | Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors | completed | Phase 2 | 20 | Children's Oncology GroupNETWORK | 4 | Aug 29, 2018 | clinicaltrials |
| NCT01727089 | Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer | completed | Phase 2 | 59 | National Cancer Institute (NCI)NIH | 3 | Aug 28, 2018 | clinicaltrials |
| NCT00915018 | Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer(NEFERTT) | completed | Phase 2 | 479 | Puma Biotechnology, Inc.INDUSTRY | 35 | Aug 22, 2018 | clinicaltrials |
| NCT01978236 | Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites | terminated | Phase 2 | 6 | GlaxoSmithKlineINDUSTRY | 2 | Aug 17, 2018 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials